Taltz (ixekizumab, Eli Lilly), a biologic injection medication for psoriasis, shows a high level of effectiveness and the latest research demonstrates that the clear-skin response which so many pat…
Taltz (ixekizumab, Eli Lilly), a biologic injection medication for psoriasis, shows a high level of effectiveness and the latest research demonstrates that the clear-skin response which so many patients benefit from when they use Taltz keeps up for at least four years after starting treatment.
Taltz first became available in 2016 for moderate to severe plaque psoriasis after extensive clinical trials showed positive results for psoriasis patients, in terms of skin clearance, joint involvement, and quality of life. These trials showed that Taltz improves psoriasis by more than 75% in the majority of patients (80%) after three months of using the medication. On the heels of this approval, the FDA added additional approvals in 2017 for active psoriatic arthritis and in 2018 for psoriasis affecting the genital area.
Taltz is based on an antibody that binds to a particular protein (interleukin 17-A) so that the inflammatory response of the body is inhibited. To use Taltz, a patient receives two initial injections then follow-up injections every few weeks thereafter (with the intervals based on the type of psoriasis).
The research clearly shows that most people benefit from starting treatment with Taltz, but as a newer medication, the research on how long these benefits might persist took a while to come in. But they have now, and it’s very positive. The latest study results, which were presented at the American Academy of Dermatology Annual Meeting, reported Taltz to be safely used with sustained efficacy over a four-year study period in patients with moderate to severe psoriasis.
This continues the good news story about Taltz that’s been making headlines since the initial 2016 FDA approval. BioPlus works with many psoriasis patients on their journey to better health and we’re ready to help your patients next!
Lebwohl MG, et al. Abstract 10011. Presented at: American Academy of Dermatology Annual Meeting; March 1-5, 2019; Washington, D.C.
|Read on: Taltz: The Good News Keeps Coming|